Abstract
Cholesterol is an important metabolite and membrane component and is enriched in the brain owing to its role in neuronal maturation and function. In the adult brain, cholesterol is produced locally, predominantly by astrocytes. When cholesterol has been used, recycled and catabolized, the derivatives are excreted across the blood–brain barrier. Abnormalities in any of these steps can lead to neurological dysfunction. Here, we examine how precise interactions between cholesterol production and its use and catabolism in neurons ensures cholesterol homeostasis to support brain function. As an example of a neurological disease associated with cholesterol dyshomeostasis, we summarize evidence from animal models of Huntington disease (HD), which demonstrate a marked reduction in cholesterol biosynthesis with clinically relevant consequences for synaptic activity and cognition. In addition, we examine the relationship between cholesterol loss in the brain and cognitive decline in ageing. We then present emerging therapeutic strategies to restore cholesterol homeostasis, focusing on evidence from HD mouse models.
Key points
-
Cholesterol homeostasis in the brain is essential for healthy neuronal physiology, and dyshomeostasis of the cholesterol pathway has been implicated in neurological diseases and age-related neuropathology.
-
Reduced cholesterol biosynthesis and levels are found in the brain of animal models of neurological diseases, including Huntington’s disease (HD), as well as in aged animals.
-
Strategies that increase cholesterol biosynthesis and/or levels in the brain, including adeno-associated viral delivery of genes involved in cholesterol homeostasis or direct delivery of exogenous cholesterol, restore neuronal physiology, cognitive decline and healthy behaviour in animal models of HD and ageing.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Jurevics, H. & Morell, P. Cholesterol for synthesis of myelin is made locally, not imported into brain. J. Neurochem. 64, 895–901 (1995).
Dietschy, J. M. & Turley, S. D. Cholesterol metabolism in the central nervous system during early development and in the mature animal. J. Lipid Res. 45, 1375–1397 (2004).
Dietschy, J. M. Central nervous system: cholesterol turnover, brain development and neurodegeneration. Biol. Chem. 390, 287–293 (2009).
Maxfield, F. & Tabas, I. Role of cholesterol and lipid organization in disease. Nature 438, 612–621 (2005).
Mauch, D. et al. CNS synaptogenesis promoted by glia-derived cholesterol. Science 294, 1354–1357 (2001).
Jia, J. Y. et al. Quantitative proteomics analysis of detergent-resistant membranes from chemical synapses: evidence for cholesterol as spatial organizer of synaptic vesicle cycling. Mol. Cell. Proteom. 5, 2060–2071 (2006).
Takamori, S. et al. Molecular anatomy of a trafficking organelle. Cell 127, 831–846 (2006).
Dason, J. S., Smith, A. J., Marin, L. & Charlton, M. P. Vesicular sterols are essential for synaptic vesicle cycling. J. Neurosci. 30, 15856–15865 (2010).
Dotti, C. G., Esteban, J. A. & Ledesma, M. D. Lipid dynamics at dendritic spines. Front. Neuroanat. 8, 76 (2014).
Hering, H., Lin, C.-C. & Sheng, M. Lipid rafts in the maintenance of synapses, dendritic spines, and surface AMPA receptor stability. J. Neurosci. 23, 3262–3271 (2003).
Allen, J. A., Halverson-Tamboli, R. A. & Rasenick, M. M. Lipid raft microdomains and neurotransmitter signalling. Nat. Rev. Neurosci. 8, 128–140 (2007).
Björkhem, I. Crossing the barrier: oxysterols as cholesterol transporters and metabolic modulators in the brain. J. Int. Med. 260, 493–508 (2006).
Radhakrishnan, A., Ikeda, Y., Joo Kwon, H., Brown, M. S. & Goldstein, J. L. Sterol-regulated transport of SREBPs from endoplasmic reticulum to Golgi: oxysterols block transport by binding to Insig. Proc. Natl Acad. Sci. USA 104, 6511–6518 (2007).
Schumacher, M. et al. Steroid hormones and neurosteroids in normal and pathological aging of the nervous system. Prog. Neurobiol. 71, 3–29 (2003).
Björkhem, I., Leoni, V. & Meaney, S. Genetic connections between neurological disorders and cholesterol metabolism. J. Lipid Res. 51, 2489–2503 (2010).
Martin, M., Dotti, C. G. & Ledesma, M. D. Brain cholesterol in normal and pathological aging. Biochim. Biophys. Acta 1801, 934–944 (2010).
Saher, G. Cholesterol metabolism in aging and age-related disorders. Annu. Rev. Neurosci. 10, 59–78 (2023).
Staurenghi, E. et al. Cholesterol dysmetabolism in Alzheimer’s disease: a starring role for astrocytes? Antioxidants 26, 1890 (2021).
Fünfschilling, U., Saher, G., Xiao, L., Möbius, W. & Nave, K. A. Survival of adult neurons lacking cholesterol synthesis in vivo. BMC Neurosci. 8, 1 (2007).
Fünfschilling, U. et al. Critical time window of neuronal cholesterol synthesis during neurite outgrowth. J. Neurosci. 32, 7632–7645 (2012).
Zhang, J. & Liu, Q. Cholesterol metabolism and homeostasis in the brain. Protein Cell 6, 254–264 (2015).
Shi, Q., Chen, J., Zou, X. & Tang, X. Intracellular cholesterol synthesis and transport. Front. Cell Dev. Biol. 21, 819281 (2022).
Björkhem, I. et al. Cholesterol homeostasis in human brain: turnover of 24S-hydroxycholesterol and evidence for a cerebral origin of most of this oxysterol in the circulation. J. Lipid Res. 39, 1594–1600 (1998).
Russell, D. W., Halford, R. W., Ramirez, D. M., Shah, R. & Kotti, T. Cholesterol 24-hydroxylase: an enzyme of cholesterol turnover in the brain. Annu. Rev. Biochem. 78, 1017–1040 (2009).
Nieweg, K. et al. Marked differences in cholesterol synthesis between neurons and glial cells from postnatal rats. J. Neurochem. 109, 125–134 (2009).
Mitsche, M. A., McDonald, J. G., Hobbs, H. H. & Cohen, J. C. Flux analysis of cholesterol biosynthesis in vivo reveals multiple tissue and cell-type specific pathways. Elife 4, e07999 (2015).
Hua, X. et al. SREBP-2, a second basic-helix-loop-helix-leucine zipper protein that stimulates transcription by binding to a sterol regulatory element. Proc. Natl Acad. Sci. USA 90, 1603–1607 (1993).
Shimano, H. & Sato, R. SREBP-regulated lipid metabolism: convergent physiology-divergent pathophysiology. Nat. Rev. Endocrinol. 13, 710–730 (2017).
Camargo, N., Smit, A. B. & Verheijen, M. H. G. SREBPs: SREBP function in glia–neuron interactions. FEBS J. 276, 628–636 (2009).
Ferris, H. A. et al. Loss of astrocyte cholesterol synthesis disrupts neuronal function and alters whole-body metabolism. Proc. Natl Acad. Sci. USA 114, 1189–1194 (2017).
Valenza, M. et al. Disruption of astrocyte–neuron cholesterol cross talk affects neuronal function in Huntington’s disease. Cell Death Differ. 22, 690–702 (2015).
Camargo, N. et al. High-fat diet ameliorates neurological deficits caused by defective astrocyte lipid metabolism. FASEB J. 26, 4302–4315 (2012).
van Deijk, A. F. et al. Astrocyte lipid metabolism is critical for synapse development and function in vivo. Glia 65, 670–682 (2017).
Zhang, Y. et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J. Neurosci. 3, 11929–11947 (2014).
Zhang, Y. et al. Purification and characterization of progenitor and mature human astrocytes reveals transcriptional and functional differences with mouse. Neuron 6, 37–53 (2016).
Chai, H. et al. Neural circuit-specialized astrocytes: transcriptomic, proteomic, morphological, and functional evidence. Neuron 95, 531–549 (2017).
Batiuk, M. Y. et al. Identification of region-specific astrocyte subtypes at single cell resolution. Nat. Commun. 11, 1220 (2020).
Al-Dalahmah, O. et al. Single-nucleus RNA-seq identifies Huntington disease astrocyte states. Acta Neuropathol. Commun. 8, 19 (2020).
Valenza, M. et al. Cholesterol defect is marked across multiple rodent models of Huntington’s disease and is manifest in astrocytes. J. Neurosci. 30, 10844–10850 (2010).
Benraiss, A. et al. Cell-intrinsic glial pathology is conserved across human and murine models of Huntington’s disease. Cell Rep. 36, 109308 (2021).
Itoh, Y. & Voskuhl, R. R. Cell specificity dictates similarities in gene expression in multiple sclerosis, Parkinson’s disease, and Alzheimer’s disease. PLoS ONE 12, e0181349 (2017).
Boisvert, M. M., Erikson, G. A., Shokhirev, M. N. & Allen, N. J. The aging astrocyte transcriptome from multiple regions of the mouse brain. Cell Rep. 22, 269–285 (2018).
Liu, Q. et al. Neuronal LRP1 knockout in adult mice leads to impaired brain lipid metabolism and progressive, age-dependent synapse loss and neurodegeneration. J. Neurosci. 30, 17068–17078 (2010).
Pfrieger, F. W. & Ungerer, N. Cholesterol metabolism in neurons and astrocytes. Prog. Lipid Res. 4, 357–371 (2011).
Björkhem, I., Lütjohann, D., Breuer, O., Sakinis, A. & Wennmalm, A. Importance of a novel oxidative mechanism for elimination of brain cholesterol. Turnover of cholesterol and 24(S)-hydroxycholesterol in rat brain as measured with 18O2 techniques in vivo and in vitro. J. Biol. Chem. 272, 30178–30184 (1997).
Qian, L., Chai, A. B., Gelissen, I. C. & Brown, A. J. Balancing cholesterol in the brain: from synthesis to disposal. Explor. Neuroprot. Ther. 2, 1–27 (2022).
Petrov, A. M. & Pikuleva, I. A. Cholesterol 24-hydroxylation by CYP46A1: benefits of modulation for brain diseases. Neurotherapeutics 16, 635–648 (2019).
Ramirez, D. M. O., Andersson, S. & Russell, D. W. Neuronal expression and subcellular localization of cholesterol 24-hydroxylase in the mouse brain. J. Comp. Neurol. 507, 1676–1693 (2008).
Lund, E. G., Guileyardo, J. M. & Russell, D. W. cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain. Proc. Natl Acad. USA 96, 7238–7243 (1999).
Lutjohann, D. et al. Cholesterol homeostasis in human brain: evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation (cerebrospinal fluid/oxysterols/plasma/stable isotopes). Med. Sci. 93, 9799–9804 (1996).
Lund, E. G. et al. Knockout of the cholesterol 24-hydroxylase gene in mice reveals a brain-specific mechanism of cholesterol turnover. J. Biol. Chem. 278, 22980–22988 (2003).
Meaney, S., Lütjohann, D., Diczfalusy, U. & Björkhem, I. Formation of oxysterols from different pools of cholesterol as studied by stable isotope technique: cerebral origin of most circulating 24S-hydroxycholesterol in rats, but not in mice. Biochim. Biophys. Acta 1486, 293–298 (2020).
Leoni, V. & Caccia, C. 24S-hydroxycholesterol in plasma: a marker of cholesterol turnover in neurodegenerative diseases. Biochimie 95, 595–612 (2013).
Courtney, R. & Landreth, G. E. LXR regulation of brain cholesterol: from development to disease. Trends Endocrinol. Metab. 27, 404–414 (2016).
Abildayeva, K. et al. 24(S)-hydroxycholesterol participates in a liver X receptor-controlled pathway in astrocytes that regulates apolipoprotein E-mediated cholesterol efflux. J. Biol. Chem. 281, 12799–12808 (2006).
Liang, Y. et al. A liver X receptor and retinoid X receptor heterodimer mediates apolipoprotein E expression, secretion and cholesterol homeostasis in astrocytes. J. Neurochem. 88, 623–634 (2004).
Shafaati, M. et al. Enhanced production of 24S-hydroxycholesterol is not sufficient to drive liver X receptor target genes in vivo. J. Intern. Med. 270, 377–387 (2011).
Wang, L. et al. Liver X receptors in the central nervous system: from lipid homeostasis to neuronal degeneration. Proc. Natl Acad. Sci. USA 99, 13878–13883 (2002).
Mast, N. et al. Transcriptional and post-translational changes in the brain of mice deficient in cholesterol removal mediated by cytochrome P450 46A1 (CYP46A1). PLoS ONE 12, e0187168 (2017). Erratum in: PLoS ONE 13, e0191058 (2018).
Boussicault, L. et al. CYP46A1, the rate-limiting enzyme for cholesterol degradation, is neuroprotective in Huntington’s disease. Brain 139, 953–970 (2016).
Pfrieger, F. W. Cholesterol homeostasis and function in neurons of the central nervous system. Cell. Mol. Life Sci. 60, 1158–1171 (2003).
Hussain, G. et al. Role of cholesterol and sphingolipids in brain development and neurological diseases. Lipids Health Dis. 18, 26 (2019).
Lu, F., Ferriero, M. D. & Jiang, X. Cholesterol in brain development and perinatal brain injury: more than a building block. Curr. Neuropharmacol. 20, 1400–1412 (2022).
Yang, F. et al. An ARC/mediator subunit required for SREBP control of cholesterol and lipid homeostasis. Nature 442, 700–704 (2006).
Smith, A. J., Sugita, S. & Charlton, M. P. Cholesterol-dependent kinase activity regulates transmitter release from cerebellar synapses. J. Neurosci. 30, 6116–6121 (2010).
Churchward, M. A. & Coorssen, J. R. Cholesterol, regulated exocytosis and the physiological fusion machine. Biochem. J. 423, 1–14 (2009).
Thiele, C., Hannah, M. J., Fahrenholz, F. & Huttner, W. B. Cholesterol binds to synaptophysin and is required for biogenesis of synaptic vesicles. Nat. Cell Biol. 2, 42–49 (2000).
White, D. N. & Stowell, M. H. B. Room for two: the synaptophysin/synaptobrevin complex. Front. Synaptic Neurosci. 13, 740318 (2021).
Man, W. K. et al. The docking of synaptic vesicles on the presynaptic membrane induced by α-synuclein is modulated by lipid composition. Nat. Commun. 12, 927 (2021).
Korinek, M. et al. Cholesterol modulates presynaptic and postsynaptic properties of excitatory synaptic transmission. Sci. Rep. 10, 12651 (2020).
Fantini, J. & Barrantes, F. J. Sphingolipid/cholesterol regulation of neurotransmitter receptor conformation and function. Biochim. Biophys. Acta Biomembranes 1788, 2345–2361 (2009).
Postila, P. A. & Róg, T. A perspective: active role of lipids in neurotransmitter dynamics. Mol. Neurobiol. 57, 910–925 (2020).
Sodero, A. O. et al. Cholesterol loss during glutamate-mediated excitotoxicity. EMBO J. 31, 1764–1773 (2012).
Hardingham, G. E. & Bading, H. Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat. Rev. Neurosci. 11, 682–696 (2010).
Vanhoutte, P. & Bading, H. Opposing roles of synaptic and extrasynaptic NMDA receptors in neuronal calcium signalling and BDNF gene regulation. Curr. Opin. Neurobiol. 13, 366–371 (2003).
Martin, M. G. et al. Constitutive hippocampal cholesterol loss underlies poor cognition in old rodents. EMBO Mol. Med. 6, 902–917 (2014).
Klein, R. L. et al. Long-term actions of vector-derived nerve growth factor or brain-derived neurotrophic factor on choline acetyltransferase and Trk receptor levels in the adult rat basal forebrain. Neuroscience 90, 815–821 (1999).
Fantini, J., Epand, R. M., Barrantes, F. J. in Direct Mechanisms in Cholesterol Modulation of Protein Function (eds Rosenhouse-Dantsker, A. & Bukiya, A.) 3–25 (Springer, 2019).
Casarotto, P. C. et al. Antidepressant drugs act by directly binding to TRKB neurotrophin receptors. Cell 184, 1299–1313.e19 (2021).
Minichiello, L. TrkB signalling pathways in LTP and learning. Nat. Rev. Neurosci. 10, 850–860 (2009).
Platt, F. M. et al. Disorders of cholesterol metabolism and their unanticipated convergent mechanisms of disease. Annu. Rev. Genomics Hum. Genet. 15, 173–194 (2014).
Martín, M. G., Pfrieger, F. & Dotti, C. G. Cholesterol in brain disease: sometimes determinant and frequently implicated. EMBO Rep. 15, 1036–1052 (2014).
Arenas, F., Garcia-Ruiz, C. & Fernandez-Checa, J. C. Intracellular cholesterol trafficking and impact in neurodegeneration. Front. Mol. Neurosci. 10, 382 (2017).
Dai, L. et al. Cholesterol metabolism in neurodegenerative diseases: molecular mechanisms and therapeutic targets. Mol. Neurobiol. 58, 2183–2201 (2021).
Paulsen, J. S. et al. Prediction of manifest Huntington’s disease with clinical and imaging measures: a prospective observational study. Lancet Neurol. 13, 1193–1201 (2014).
Sipione, S. et al. Early transcriptional profiles in huntingtin-inducible striatal cells by microarray analyses. Hum. Mol. Genet. 11, 1953–1965 (2002).
Valenza, M. et al. Dysfunction of the cholesterol biosynthetic pathway in Huntington’s disease. J. Neurosci. 25, 9932–9939 (2005).
Diaz-Castro, B., Gangwani, M. R., Yu, X., Coppola, G. & Khakh, B. S. Astrocyte molecular signatures in Huntington’s disease. Sci. Transl. Med. 11, eaaw8546 (2019).
Shankaran, M. et al. Early and brain region-specific decrease of de novo cholesterol biosynthesis in Huntington’s disease: a cross-validation study in Q175 knock-in mice. Neurobiol. Dis. 98, 66–76 (2017).
di Pardo, A. et al. Mutant huntingtin interacts with the sterol regulatory element-binding proteins and impairs their nuclear import. Hum. Mol. Genet. 29, 418–431 (2020).
Birolini, G. et al. SREBP2 gene therapy targeting striatal astrocytes ameliorates Huntington’s disease phenotypes. Brain 144, 3175–3190 (2021).
Valenza, M. et al. Cholesterol biosynthesis pathway is disturbed in YAC128 mice and is modulated by huntingtin mutation. Hum. Mol. Genet. 16, 2187–2198 (2007).
Valenza, M. et al. Progressive dysfunction of the cholesterol biosynthesis pathway in the R6/2 mouse model of Huntington’s disease. Neurobiol. Dis. 28, 133–142 (2007).
Birolini, G. et al. Striatal infusion of cholesterol promotes dose‐dependent behavioral benefits and exerts disease‐modifying effects in Huntington’s disease mice. EMBO Mol. Med. 12, e12519 (2020).
Birolini, G. et al. Insights into kinetics, release, and behavioral effects of brain-targeted hybrid nanoparticles for cholesterol delivery in Huntington’s disease. J. Control. Rel. 330, 587–598 (2021).
Birolini, G. et al. Chronic cholesterol administration to the brain supports complete and long-lasting cognitive and motor amelioration in Huntington’s disease. Pharmacol. Res. 17, 106823 (2023).
Trushina, E. et al. Mutant huntingtin inhibits clathrin-independent endocytosis and causes accumulation of cholesterol in vitro and in vivo. Hum. Mol. Genet. 15, 3578–3591 (2006).
del Toro, D. et al. Altered cholesterol homeostasis contributes to enhanced excitotoxicity in Huntington’s disease. J. Neurochem. 115, 153–167 (2010).
Kacher, R. et al. CYP46A1 gene therapy deciphers the role of brain cholesterol metabolism in Huntington’s disease. Brain 142, 2432–2450 (2019).
Valenza, M. & Cattaneo, E. Emerging roles for cholesterol in Huntington’s disease. Trends Neurosci. 34, 474–486 (2011).
Marullo, M. et al. Pitfalls in the detection of cholesterol in Huntington’s disease models. PLoS Curr. 4, e505886e9a1968 (2012).
Yutuc, E. et al. Localization of sterols and oxysterols in mouse brain reveals distinct spatial cholesterol metabolism. Proc. Natl Acad. Sci. USA 117, 5749–5760 (2020).
Li, T. et al. Ion mobility-based sterolomics reveals spatially and temporally distinctive sterol lipids in the mouse brain. Nat. Commun. 12, 4343 (2021).
Capolupo, L. et al. Sphingolipids control dermal fibroblast heterogeneity. Science 376, eabh1623 (2022).
Kreilaus, F., Spiro, A. S., McLean, C. A., Garner, B. & Jenner, A. M. Evidence for altered cholesterol metabolism in Huntington’s disease post mortem brain tissue. Neuropathol. Appl. Neurobiol. 42, 535–546 (2016).
Phillips, G. R. et al. Cholesteryl ester levels are elevated in the caudate and putamen of Huntington’s disease patients. Sci. Rep. 10, 20314 (2020).
Leoni, V. et al. Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntington’s disease. Brain 131, 2851–2859 (2008).
Leoni, V. et al. Whole body cholesterol metabolism is impaired in Huntington’s disease. Neurosci. Lett. 494, 245–249 (2011).
Leoni, V., Long, J. D., Mills, J. A., di Donato, S. & Paulsen, J. S. Plasma 24S-hydroxycholesterol correlation with markers of Huntington disease progression. Neurobiol. Dis. 55, 37–43 (2013).
Katsuno, M., Adachi, H. & Sobue, G. Getting a handle on Huntington’s disease: the case for cholesterol. Nat. Med. 15, 253–254 (2009).
Ledesma, M. D., Martin, M. G. & Dotti, C. G. Lipid changes in the aged brain: effect on synaptic function and neuronal survival. Prog. Lipid Res. 51, 23–35 (2012).
Söderberg, M., Edlund, C., Kristensson, K. & Dallner, G. Lipid compositions of different regions of the human brain during aging. J. Neurochem. 54, 415–423 (1990).
Svennerholm, L., Boström, K., Jungbjer, B. & Olsson, L. Membrane lipids of adult human brain: lipid composition of frontal and temporal lobe in subjects of age 20 to 100 years. J. Neurochem. 63, 1802–1811 (1994).
Svennerholm, L., Boström, K. & Jungbjer, B. Changes in weight and compositions of major membrane components of human brain during the span of adult human life of Swedes. Acta Neuropathol. 94, 345–352 (1997).
Thelen, K. M., Falkai, P., Bayer, T. A. & Lütjohann, D. Cholesterol synthesis rate in human hippocampus declines with aging. Neurosci. Lett. 403, 15–19 (2006).
Martin, M. G. et al. Cholesterol loss enhances TrkB signaling in hippocampal neurons aging in vitro. Mol. Biol. Cell 19, 2101–2112 (2008).
Sodero, A. O. et al. Regulation of tyrosine kinase B activity by the Cyp46/cholesterol loss pathway in mature hippocampal neurons: relevance for neuronal survival under stress and in aging. J. Neurochem. 116, 747–755 (2011).
Egawa, J., Pearn, M. L., Lemkuil, B. P., Patel, P. M. & Head, B. P. Membrane lipid rafts and neurobiology: age-related changes in membrane lipids and loss of neuronal function. J. Physiol. 594, 4565–4579 (2016).
Colin, J. et al. Membrane raft domains and remodeling in aging brain. Biochimie 130, 178–187 (2016).
Díaz, M., Fabelo, N., Ferrer, I. & Marín, R. “Lipid raft aging” in the human frontal cortex during nonpathological aging: gender influences and potential implications in Alzheimer’s disease. Neurobiol. Aging 67, 42–52 (2018).
Díaz, M. et al. Biophysical alterations in lipid rafts from human cerebral cortex associate with increased BACE1/AβPP interaction in early stages of Alzheimer’s disease. J. Alzheimers Dis. 43, 1185–1198 (2015).
Jick, H. et al. Statins and the risk of dementia. Lancet 356, 1627–1631 (2000).
Pikuleva, I. A. & Cartier, N. Cholesterol hydroxylating cytochrome P450 46A1: from mechanisms of action to clinical applications. Front. Aging Neurosci. 13, 696778 (2021).
Martin, M. G. et al. Cyp46-mediated cholesterol loss promotes survival in stressed hippocampal neurons. Neurobiol. Aging 32, 933–943 (2011).
Trovo, L. et al. Low hippocampal PI(4,5)P2 contributes to reduced cognition in old mice as a result of loss of MARCKS. Nat. Neurosci. 16, 449–458 (2013).
Brudvig, J. J. & Weimer, J. M. X MARCKS the spot: myristoylated alanine-rich C kinase substrate in neuronal function and disease. Front. Cell. Neurosci. 9, 407 (2015).
Mancini, A., de Iure, A. & Picconi, B. Chapter 2 – Basic mechanisms of plasticity and learning. Handb. Clin. Neurol. 184, 21–34 (2022).
Malenka, R. C. & Bear, M. F. LTP and LTD: an embarrassment of riches. Neuron 44, 5–21 (2004).
Frank, C. et al. Cholesterol depletion inhibits synaptic transmission and synaptic plasticity in rat hippocampus. Exp. Neurol. 212, 407–414 (2008).
Palomer, E., Carretero, J., Benvegnù, S., Dotti, C. G. & Martin, M. G. Neuronal activity controls Bdnf expression via Polycomb de-repression and CREB/CBP/JMJD3 activation in mature neurons. Nat. Commun. 7, 11081 (2016).
Paul, S. M. et al. The major brain cholesterol metabolite 24(S)-hydroxycholesterol is a potent allosteric modulator of N-methyl-d-aspartate receptors. J. Neurosci. 33, 17290–17300 (2013).
Kotti, T. J., Ramirez, D. M., Pfeiffer, B. E., Huber, K. M. & Russell, D. W. Brain cholesterol turnover required for geranylgeraniol production and learning in mice. Proc. Natl Acad. Sci. USA 103, 3869–3874 (2006).
Moutinho, M. et al. Neuronal cholesterol metabolism increases dendritic outgrowth and synaptic markers via a concerted action of GGTase-I and Trk. Sci. Rep. 6, 30928 (2016).
Sodero, A. O. 24S-hydroxycholesterol: cellular effects and variations in brain diseases. J. Neurochem. 157, 899–918 (2021).
Williams, D. M., Finan, C., Schmidt, A. F., Burgess, S. & Hingorani, A. D. Lipid lowering and Alzheimer disease risk: a Mendelian randomization study. Ann. Neurol. 87, 30–39 (2020).
Rodriguez, G. A., Burns, M. P., Weeber, E. J. & Rebeck, G. W. Young APOE4 targeted replacement mice exhibit poor spatial learning and memory, with reduced dendritic spine density in the medial entorhinal cortex. Learn. Mem. 20, 256–266 (2013).
Liu, L. et al. Glial lipid droplets and ROS induced by mitochondrial defects promote neurodegeneration. Cell 160, 177–190 (2015).
Nunes, V. S., Cazita, P. M., Catanozi, S., Nakandakare, E. R. & Quintão, E. C. R. Decreased content, rate of synthesis and export of cholesterol in the brain of apoE knockout mice. J. Bioenerg. Biomembr. 50, 283–287 (2018).
Lane-Donovan, C. et al. Genetic restoration of plasma apoe improves cognition and partially restores synaptic defects in ApoE-deficient mice. J. Neurosci. 36, 10141–10150 (2016).
Lane-Donovan, C. & Herz, J. ApoE, ApoE receptors, and the synapse in Alzheimer’s disease. Trends Endocrinol. Metab. 28, 273–284 (2017).
Fuentes, D. et al. Age-related changes in the behavior of apolipoprotein E knockout mice. Behav. Sci. 8, 33 (2018).
Bourbon-Teles, J. et al. Myelin breakdown in human Huntington’s disease: multi-modal evidence from diffusion MRI and quantitative magnetization transfer. Neuroscience 403, 79–92 (2019).
Reading, S. A. et al. Regional white matter change in pre-symptomatic Huntington’s disease: a diffusion tensor imaging study. Psychiatry Res. 140, 55–62 (2005).
Rosas, H. D. et al. Diffusion tensor imaging in presymptomatic and early Huntington’s disease: selective white matter pathology and its relationship to clinical measures. Mov. Disord. 21, 1317–1325 (2006).
Rosas, H. D. et al. Complex spatial and temporally defined myelin and axonal degeneration in Huntington disease. Neuroimage Clin. 20, 236–242 (2018).
Ferrari Bardile, C. et al. Intrinsic mutant HTT-mediated defects in oligodendroglia cause myelination deficits and behavioral abnormalities in Huntington disease. Proc. Natl Acad. Sci. USA 116, 9622–9627 (2019).
Xiang, Z. et al. Peroxisome-proliferator-activated receptor gamma coactivator 1 α contributes to dysmyelination in experimental models of Huntington’s disease. J. Neurosci. 31, 9544–9553 (2011).
Cui, L. et al. Transcriptional repression of PGC-1α by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 127, 59–69 (2006).
Weydt, P. et al. Thermoregulatory and metabolic defects in Huntington’s disease transgenic mice implicate PGC-1α in Huntington’s disease neurodegeneration. Cell Metab. 4, 349–362 (2006).
Weydt, P. et al. The gene coding for PGC-1α modifies age at onset in Huntington’s disease. Mol. Neurodegener. 4, 3 (2009).
Finck, B. N. & Kelly, D. P. PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. J. Clin. Invest. 116, 615–622 (2006).
Menalled, L. B. et al. Comprehensive behavioral and molecular characterization of a new knock-in mouse model of Huntington’s disease: zQ175. PLoS ONE 7, e49838 (2012).
Southwell, A. L. et al. An enhanced Q175 knock-in mouse model of Huntington disease with higher mutant huntingtin levels and accelerated disease phenotypes. Hum. Mol. Genet. 25, 3654–3675 (2016).
Hudry, E. et al. Adeno-associated virus gene therapy with cholesterol 24-hydroxylase reduces the amyloid pathology before or after the onset of amyloid plaques in mouse models of Alzheimer’s disease. Mol. Ther. 18, 44–53 (2010).
Burlot, M. A. et al. Cholesterol 24-hydroxylase defect is implicated in memory impairments associated with Alzheimer-like Tau pathology. Hum. Mol. Genet. 24, 5965–5976 (2015).
Nóbrega, C. et al. Restoring brain cholesterol turnover improves autophagy and has therapeutic potential in mouse models of spinocerebellar ataxia. Acta Neuropathol. 138, 837–858 (2019).
Mast, N. et al. Pharmacologic stimulation of cytochrome P450 46A1 and cerebral cholesterol turnover in mice. J. Biol. Chem. 289, 3529–3538 (2014).
Anderson, K. W. et al. Mapping of the allosteric site in cholesterol hydroxylase CYP46A1 for efavirenz, a drug that stimulates enzyme activity. J. Biol. Chem. 291, 11876–11886 (2016).
Mast, N. et al. Cholesterol-metabolizing enzyme cytochrome P450 46A1 as a pharmacologic target for Alzheimer’s disease. Neuropharmacology 123, 465–476 (2017).
Petrov, A. M., Mast, N., Li, Y. & Pikuleva, I. A. The key genes, phosphoproteins, processes, and pathways affected by efavirenz-activated CYP46A1 in the amyloid-decreasing paradigm of efavirenz treatment. FASEB J. 33, 8782–8798 (2019).
Tong, X. et al. Astrocyte Kir4.1 ion channel deficits contribute to neuronal dysfunction in Huntington’s disease model mice. Nat. Neurosci. 17, 694–703 (2014).
Sabatino, D. E. et al. American Society of Gene and Cell Therapy (ASGCT) working group on AAV integration. Evaluating the state of the science for adeno-associated virus integration: an integrated perspective. Mol. Ther. 30, 2646–2663 (2022).
Challis, R. C. et al. Adeno-associated virus toolkit to target diverse brain cells. Annu. Rev. Neurosci. 45, 447–469 (2022).
Huang, L. et al. Challenges in adeno-associated virus-based treatment of central nervous system diseases through systemic injection. Life Sci. 270, 119142 (2021).
Kang, L. et al. AAV vectors applied to the treatment of CNS disorders: clinical status and challenges. J. Control. Rel. 355, 458–473 (2023).
Almoshari, Y. Osmotic pump drug delivery systems – a comprehensive review. Pharmaceuticals 15, 1430 (2022).
Dagdeviren, C. et al. Miniaturized neural system for chronic, local intracerebral drug delivery. Sci. Transl. Med. 10, eaan2742 (2018).
Spandana, K. M. A. et al. A comprehensive review of nano drug delivery system in the treatment of CNS disorders. J. Drug Deliv. Sci. Technol. 57, 101628 (2020).
Abdellatif, A. A. H. et al. Nano-scale delivery: a comprehensive review of nano-structured devices, preparative techniques, site-specificity designs, biomedical applications, commercial products, and references to safety, cellular uptake, and organ toxicity. Nanotechnol. Rev. 10, 1493–1559 (2021).
Tosi, G. et al. Targeting the central nervous system: in vivo experiments with peptide-derivatized nanoparticles loaded with loperamide and rhodamine-123. J. Control. Rel. 122, 1–9 (2007).
Valenza, M. et al. Cholesterol‐loaded nanoparticles ameliorate synaptic and cognitive function in Huntington’s disease mice. EMBO Mol. Med. 7, 1547–1564 (2015).
Belletti, D. et al. Hybrid nanoparticles as a new technological approach to enhance the delivery of cholesterol into the brain. Int. J. Pharm. 543, 300–310 (2018).
Lammers, T. & Ferrari, M. The success of nanomedicine. Nano Today 31, 100853 (2020).
Vu, M. N., Kelly, H. G., Kent, S. J. & Wheatley, A. K. Current and future nanoparticle vaccines for COVID-19. EBioMedicine 74, 103699 (2021).
Lee Ventola, C. Progress in nanomedicine: approved and investigational nanodrugs. P. T. 42, 742–755 (2017).
Stater, E. P., Sonay, A. Y., Hart, C. & Grimm, J. The ancillary effects of nanoparticles and their implications for nanomedicine. Nat. Nanotechnol. 16, 1180–1194 (2021).
Friedrichs, S. & Bowman, D. M. COVID-19 may become nanomedicine’s finest hour yet. Nat. Nanotechnol. 16, 362–364 (2021).
Nikolova, M. P., Kumar, E. M. & Chavali, M. S. Updates on responsive drug delivery based on liposome vehicles for cancer treatment. Pharmaceutics 14, 2195 (2022).
Bulbake, U., Doppalapudi, S., Kommineni, N. & Khan, W. Liposomal formulations in clinical use: an updated review. Pharmaceutics 9, 12 (2017).
Liu, Y. et al. Liposome-based multifunctional nanoplatform as effective therapeutics for the treatment of retinoblastoma. Acta Pharm. Sin. B 12, 2731–2739 (2022).
Safra, T. et al. Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann. Oncol. 11, 1029–1033 (2000).
Xing, M., Yan, F., Yu, S. & Shen, P. Efficacy and cardiotoxicity of liposomal doxorubicin-based chemotherapy in advanced breast cancer: a meta-analysis of ten randomized controlled trials. PLoS ONE 10, e0133569 (2015).
Passoni, A. et al. Efficacy of cholesterol nose-to-brain delivery for brain targeting in huntington’s disease. ACS Chem. Neurosci. 11, 367–372 (2020).
Hong, S. S., Oh, K. T., Choi, H. G. & Lim, S. J. Liposomal formulations for nose-to-brain delivery: recent advances and future perspectives. Pharmaceutics 11, 540 (2019).
Jeong, S. H., Jang, J. H. & Lee, Y. B. Drug delivery to the brain via the nasal route of administration: exploration of key targets and major consideration factors. J. Pharm. Investig. 53, 119–152 (2023).
Birolini, G. Cholesterol Ddysfunction in Huntington’s Disease: Working Toward a Therapeutical Approach. Dissertation, Univ. Milan (2021).
Lueptow, L. M. Novel object recognition test for the investigation of learning and memory in mice. J. Vis. Exp. 126, 55718 (2017).
Rodriguiz, R. M., Wetsel, W. C. in Animal Models of Cognitive Impairment (eds Levin, E. D. & Buccafusco, J. J.) Ch. 12 (CRC Press/Taylor & Francis, 2006).
d’Isa, R., Comi, G. & Leocani, L. Apparatus design and behavioural testing protocol for the evaluation of spatial working memory in mice through the spontaneous alternation T-maze. Sci. Rep. 11, 21177 (2021).
Kraeuter, A. K., Guest, P. C. & Sarnyai, Z. The Y-maze for assessment of spatial working and reference memory in mice. Methods Mol. Biol. 1916, 105–111 (2019).
Vorhees, C. V. & Williams, M. T. Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nat. Protoc. 1, 848–858 (2006).
Griffiths, W. J. & Wang, Y. Oxysterol research: a brief review. Biochem. Soc. Trans. 47, 517–526 (2019).
Haider, A. Assessment of cholesterol homeostasis in the living human brain. Sci. Transl. Med. 14, eadc9967 (2022).
Sparrow, C. P. et al. A fluorescent cholesterol analog traces cholesterol absorption in hamsters and is esterified in vivo and in vitro. J. Lipid Res. 40, 1747–1757 (1999).
Wüstner, D., Modzel, M., Lund, F. W. & Lomholt, M. A. Imaging approaches for analysis of cholesterol distribution and dynamics in the plasma membrane. Chem. Phys. Lipids 199, 106–135 (2016).
Möbius, W. et al. Immunoelectron microscopic localization of cholesterol using biotinylated and non-cytolytic perfringolysin O. J. Histochem. Cytochem. 50, 43–55 (2002).
Ohno-Iwashita, Y. et al. Cholesterol-binding toxins and anti-cholesterol antibodies as structural probes for cholesterol localization. Subcell. Biochem. 51, 597–621 (2010).
Mitroi, D. N. et al. NPC 1 enables cholesterol mobilization during long‐term potentiation that can be restored in Niemann–Pick disease type C by CYP 46A1 activation. EMBO Rep. 20, e48143 (2019).
Angelini, R. et al. Visualizing cholesterol in the brain by on-tissue derivatization and quantitative mass spectrometry imaging. Anal. Chem. 93, 4932–4943 (2021).
Author information
Authors and Affiliations
Contributions
All authors wrote the article, and reviewed and edited the manuscript before submission.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Peer review
Peer review information
Nature Reviews Neurology thanks the anonymous reviewers for their contribution to the peer review of this work.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Related links
Adult Astrocyte RNA-Seq Explorer: http://astrocyternaseq.org/
Brain RNA-Seq: http://brainrnaseq.org
HD single-nucleus RNA-seq explorer: https://vmenon.shinyapps.io/hd_sn_rnaseq/
Human Protein Atlas: https://www.proteinatlas.org/
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Valenza, M., Birolini, G. & Cattaneo, E. The translational potential of cholesterol-based therapies for neurological disease. Nat Rev Neurol 19, 583–598 (2023). https://doi.org/10.1038/s41582-023-00864-5
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41582-023-00864-5
This article is cited by
-
Hybrid nanostructures for neurodegenerative disease theranostics: the art in the combination of biomembrane and non-biomembrane nanostructures
Translational Neurodegeneration (2024)
-
The associations between peripheral inflammatory and lipid parameters, white matter hyperintensity, and cognitive function in patients with non-disabling ischemic cerebrovascular events
BMC Neurology (2024)